Determination of Complement Activity by 50% Hemolysis (CH50 Assay)

The CH50 assay, also known as the 50% hemolytic complement activity test, is a functional assay that quantitatively measures the total activity of the classical complement pathway in serum by determining the dilution that lyses 50% of antibody-sensitized sheep erythrocytes. This test is widely used in clinical immunology for diagnosing complement deficiencies and immune-complex diseases, and it also supports pharmaceutical biologics testing and medical device hemocompatibility evaluation in accredited third-party laboratories. This article provides a comprehensive technical overview of the CH50 assay, covering its principle, sample requirements, testing methods, applications, and frequently asked questions.

Technical Overview

The complement system consists of more than 30 serum and cell-surface proteins that operate through three activation pathways: the classical pathway, the lectin pathway, and the alternative pathway. All three converge on the terminal common pathway, forming the membrane attack complex (C5b-9) that lyses target cells. The CH50 assay (50% hemolytic complement activity, sometimes reported as CH100 or total hemolytic complement) is a functional bioassay that evaluates the integrity of the entire classical pathway cascade, from C1 through C9.

The principle of the assay is as follows: sheep red blood cells (SRBC) are sensitized with rabbit anti-sheep erythrocyte antibody (hemolysin or amboceptor) to form EA cells (erythrocyte-antibody complexes). When serially diluted test serum is incubated with a standardized EA cell suspension, complement in the serum is activated via the classical pathway and mediates antibody-dependent hemolysis. Released hemoglobin is quantified spectrophotometrically at 540 to 541 nm, and the reciprocal of the serum dilution that produces 50% hemolysis is defined as the CH50 value, expressed in units per milliliter (U/mL).

Because hemolysis follows a sigmoidal dose-response curve, results are typically linearized using the von Krogh transformation, in which the log of the ratio of hemolyzed to non-hemolyzed cells is plotted against the log of the complement concentration. Since the assay requires all nine classical pathway components to be present and functional, a markedly reduced or absent CH50 value indicates either consumption of complement components or an inherited deficiency of any single component.

Key technical characteristics of the CH50 assay include:

• Functional, activity-based measurement rather than an antigenic quantification of individual proteins
• Detection of the combined activity of C1q, C1r, C1s, C2, C4, C3, C5, C6, C7, C8, and C9
• Typical adult reference interval of approximately 21 to 47 U/mL, depending on laboratory standardization and assay temperature
• Complementary relationship with AH50 testing, which evaluates the alternative pathway using unsensitized rabbit erythrocytes

Testing Samples

Serum (Preferred Sample Type)

Serum collected in plain tubes without anticoagulant is the recommended specimen. Blood should be allowed to clot at room temperature for 30 to 60 minutes, centrifuged promptly, and the serum separated within one to two hours of collection. Because complement components are thermolabile and degrade rapidly at room temperature, serum should be frozen at -70°C or below if testing is not performed immediately. Repeated freeze-thaw cycles must be avoided, and samples must not be heat-inactivated prior to testing.

Animal Serum for Preclinical Studies

Serum from animal species such as mice, rats, guinea pigs, rabbits, dogs, and non-human primates is frequently tested in preclinical toxicology and pharmacology studies. Species-specific reference ranges and assay conditions, including the choice of indicator erythrocytes and hemolysin, must be validated because complement activity varies considerably between species.

Plasma Samples (Generally Not Recommended)

EDTA plasma is unsuitable for functional complement assays because chelation of calcium and magnesium ions blocks both the classical and alternative pathways. Heparinized or citrated plasma may also interfere with complement activation and should only be used after method-specific validation. Serum remains the reference matrix for CH50 determination.

Medical Device Extracts

For hemocompatibility evaluation of blood-contacting medical devices, extracts are prepared according to ISO 10993-12 and incubated with human serum to assess complement-activating potential, in conjunction with activation markers specified in ISO 10993-4 (GB/T 16886.4).

Testing Items

Core testing items associated with the 50% hemolytic complement activity assay include:

• CH50 (total hemolytic complement activity, classical pathway functional assay)
• AH50 or ACH50 (alternative pathway hemolytic activity using rabbit erythrocytes)
• Individual component antigen levels, typically C3 and C4, to distinguish consumption from deficiency when interpreted alongside CH50 results
• Complement activation markers, including C3a, C4a, C5a, Bb, and SC5b-9, for biocompatibility and inflammation assessments
• Complement-dependent cytotoxicity (CDC) functional readouts for therapeutic antibody potency testing

A combined CH50 and AH50 panel, supplemented by C3 and C4 measurements, provides a complete diagnostic algorithm for localizing complement defects to a specific pathway and, when necessary, to individual components.

Testing Methods

Classical Tube-Based CH50 Assay (Mayer Method)

The reference method involves sensitizing a standardized sheep erythrocyte suspension with optimal concentrations of rabbit hemolysin to prepare EA cells. Serial dilutions of test serum are prepared in gelatin veronal-buffered saline containing calcium and magnesium ions (GVB++), mixed with EA cells, and incubated at 37°C for a defined period, typically 30 to 60 minutes. After centrifugation, hemoglobin release in the supernatant is measured at 540 to 541 nm against 100% hemolysis (water lysis) and blank (no hemolysis) controls. The dilution producing 50% lysis is calculated using the von Krogh log-log transformation, and the CH50 value is expressed as U/mL.

Microplate Spectrophotometric Assay

The tube method has been adapted to 96-well microplates, permitting reduced reagent consumption, higher throughput, and automated absorbance reading. Assay parameters such as cell concentration, sensitization level, incubation time, and temperature must be revalidated to maintain equivalence with the reference method.

ELISA-Based Pathway-Specific Assays

Commercial and in-house ELISA systems assess individual pathway activity using pathway-specific immobilized activators: immune complexes or IgM for the classical pathway, mannan for the lectin pathway, and bacterial lipopolysaccharide or rabbit erythrocyte membranes for the alternative pathway. Detection of the C5b-9 neoepitope formed at the terminal step provides a functional readout for each pathway and requires only small serum volumes.

Automated Liposome-Based Immunoassay

Liposome lysis assays encapsulate a reporter enzyme within dinitrophenyl-modified liposomes. Complement activation by surface-bound anti-DNP antibody lyses the liposomes and releases the enzyme marker, generating a signal proportional to complement activity. These assays are amenable to clinical chemistry analyzers and improve reproducibility and turnaround time.

Quality Control and Standardization

Each analytical run must include calibrator sera of known activity, normal and abnormal controls, and hemolysis controls. Laboratories follow CLSI guidance for immunological testing and method validation, and results are harmonized where possible against WHO reference materials. Inter-laboratory comparability depends on rigorous control of erythrocyte age and concentration, hemolysin lot, buffer ionic strength, incubation temperature, and pre-analytical sample handling.

Applications

Clinical Immunology and Disease Monitoring

CH50 testing is indicated in the evaluation of recurrent infections, suspected hereditary complement deficiencies, and immune-complex diseases. Markedly depressed CH50 with low C3 and C4 is characteristic of active systemic lupus erythematosus, immune-complex glomerulonephritis, and cryoglobulinemia, and serial CH50 monitoring helps track disease activity and response to therapy. An absent CH50 with normal antigen levels suggests a genetic deficiency of a single component, which is associated with susceptibility to recurrent Neisseria infections and autoimmunity.

Pharmaceutical and Biologics Quality Testing

Functional complement assays underpin complement-dependent cytotoxicity testing for therapeutic antibodies, evaluation of immune-complex formation by biologics, and assessment of complement activation as a potential adverse effect of formulated drug products. Testing supports release and stability programs in accordance with pharmacopoeial expectations and regulatory guidance.

Medical Device Biocompatibility

Complement activation is a required evaluation endpoint for blood-contacting devices under ISO 10993-4. CH50-type functional assays and activation markers such as C3a, C5a, Bb, and SC5b-9 are used to quantify the complement-activating potential of device materials and extracts, informing hemocompatibility risk assessment.

Preclinical Research and Drug Development

The assay is extensively used in the development of complement inhibitors and targeted biologics, in animal models of complement-mediated pathology, and in immunotoxicology studies, where changes in serum CH50 serve as a sensitive functional biomarker of complement modulation.

FAQ

What is the difference between CH50 and AH50?

CH50 measures the functional activity of the classical pathway using antibody-sensitized sheep erythrocytes and requires all components C1 through C9, whereas AH50 measures alternative pathway activity using unsensitized rabbit erythrocytes and requires factor B, factor D, properdin, C3, and C5 through C9. Testing both assays together allows precise localization of pathway-specific defects.

What does a low CH50 result mean?

A low CH50 indicates reduced functional complement activity, most commonly due to activation and consumption in immune-complex diseases such as systemic lupus erythematosus, or less commonly due to inherited deficiency of a single component, severe hepatic synthetic failure, or improper sample storage. Results should be interpreted together with C3, C4, and clinical findings.

What does a high CH50 result mean?

Elevated CH50 values may occur during acute-phase inflammatory responses, as complement proteins behave as positive acute-phase reactants. Mildly elevated results are generally of limited clinical specificity but may support the presence of an active inflammatory process.

Why is EDTA plasma not acceptable for CH50 testing?

EDTA chelates calcium and magnesium ions that are essential for classical and alternative pathway activation, preventing complement-mediated hemolysis and producing falsely low or absent activity. Serum is therefore the required sample type for functional testing.

What precautions are necessary for sample handling?

Samples should be processed within one to two hours of collection, frozen at -70°C or below for storage, transported on dry ice, and never subjected to heat inactivation or repeated freeze-thaw cycles. Hemolyzed or lipemic specimens should be rejected because they interfere with spectrophotometric measurement.

Which standards govern complement activity testing?

Functional complement testing is performed with reference to CLSI immunology guidance and WHO reference materials, while medical device-related complement evaluation follows ISO 10993-4 (GB/T 16886.4). Accredited third-party laboratories validate their methods against these recognized standards to ensure accurate and reproducible results.